CARL ZEISS MEDITEC ADR 1 (AFXA) — Capital Reinvestment Ratio
CARL ZEISS MEDITEC ADR 1 (AFXA) has a Capital Reinvestment Ratio of 0.36x as of September 2025, meaning it reinvests 0% of its operating cash flow (€209.86 Million) in capital expenditures (€76.59 Million). See net asset quality index of CARL ZEISS MEDITEC ADR 1 to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
CARL ZEISS MEDITEC ADR 1 Capital Reinvestment Ratio (2022–2025)
This chart tracks CARL ZEISS MEDITEC ADR 1's Capital Reinvestment Ratio across 4 annual periods. Check cash flow reinvestment rate of CARL ZEISS MEDITEC ADR 1 to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for CARL ZEISS MEDITEC ADR 1 (2022–2025)
Year-by-year Capital Reinvestment Ratio for CARL ZEISS MEDITEC ADR 1 from 2022 to 2025. For live market cap and broader valuation context, see CARL ZEISS MEDITEC ADR 1 (AFXA) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | €209.86 Million | €76.59 Million | ▼ -40.7% |
| 2024 | 0.62x | €247.32 Million | €152.20 Million | ▲ +35.6% |
| 2023 | 0.45x | €250.86 Million | €113.86 Million | ▲ +4.2% |
| 2022 | 0.44x | €188.20 Million | €81.97 Million | — |